Holen Sie sich die Stockscreener-App
87.20
0.50%
-0.44
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
What drives Soleno Therapeutics Inc. stock priceHigh-performance investment picks - PrintWeekIndia
What analysts say about Soleno Therapeutics Inc. stockSuperior capital gains - Autocar Professional
Soleno gains as Betaville cites buyout interest (update) - MSN
Soleno Therapeutics Inc. Stock Analysis and ForecastConsistent triple-digit returns - jammulinksnews.com
Is Soleno Therapeutics Inc. a good long term investmentHigh-profit capital plays - jammulinksnews.com
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics: A Strategic Capital Raise Balances M&A Optionality with Long-Term Growth Potential - AInvest
Soleno Therapeutics: Fairly Valued Despite M&A Expectations - Seeking Alpha
Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer - The Globe and Mail
Mintz Advises on Soleno Therapeutics’ $200 Million Public Offering - Mintz
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch - Investing.com Nigeria
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch By Investing.com - Investing.com South Africa
Soleno Therapeutics Announces Public Stock Offering - TipRanks
In Brief: Soleno To Raise $200m To Boost Vykat XR Launch - insights.citeline.com
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales - Investing.com Australia
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewswire
Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales - Investing.com Nigeria
Firm Advises Soleno Therapeutics on $200 Million Public Offering - Wilson Sonsini
Soleno reports preliminary Q2 revenue of $31-33 million for VYKAT XR - Investing.com Nigeria
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Soleno sales of new Prader-Willi drug rise faster than expected - BioPharma Dive
Soleno Therapeutics Prices $200 Mln Public Offering To Support VYKAT XR Launch - Nasdaq
Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com - Investing.com Canada
Soleno Therapeutics stock falls after pricing $200 million offering - Investing.com
Soleno Therapeutics prices public offering at $85 per share - Investing.com
Soleno Therapeutics prices public offering at $85 per share By Investing.com - Investing.com South Africa
Soleno Therapeutics prices $200M public offering - MSN
Soleno Therapeutics Secures $200M Public Offering to Commercialize Breakthrough Prader-Willi Treatment - Stock Titan
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales By Investing.com - Investing.com South Africa
Soleno Therapeutics: Q2 2025 Results Signal Breakout Potential in Rare Disease Market - AInvest
Soleno Therapeutics announces preliminary financial and operational results for Q2 - MarketScreener
Soleno Therapeutics' $200M Secondary Offering: Catalyst for Growth or Dilution Danger Zone? - AInvest
Soleno Therapeutics Reports Q2 Preliminary Net Revenue - MarketScreener
Soleno Therapeutics Proposes $200 Million Public Offering - MarketScreener
Soleno Therapeutics Reports Preliminary Financial Results for Q2 2025, Anticipating $31-$33 Million in Revenue from VYKAT™ XR - Nasdaq
Soleno Therapeutics Announces Preliminary Financial and - GlobeNewswire
Soleno's New Drug VYKAT XR Hits $33M Revenue in First Quarter Launch with Nearly 300 Prescribers - Stock Titan
Soleno Therapeutics (SLNO) Soars 5.93% on Regulatory Milestone - AInvest
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI) and Soleno Therapeutics (SLNO) - The Globe and Mail
Soleno Therapeutics stock price target raised to $115 by Stifel on strong Vykat demand - Investing.com South Africa
Soleno Therapeutics stock poised for success as Piper Sandler sees $2B+ potential - Investing.com Nigeria
(SLNO) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Soleno Therapeutics stock price target raised to $115 from $108 at Stifel - Investing.com Nigeria
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):